BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother 2021;76:550-60. [PMID: 33332545 DOI: 10.1093/jac/dkaa511] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
Number Citing Articles
1 Losito AR, Raffaelli F, Del Giacomo P, Tumbarello M. New Drugs for the Treatment of Pseudomonas aeruginosa Infections with Limited Treatment Options: A Narrative Review. Antibiotics 2022;11:579. [DOI: 10.3390/antibiotics11050579] [Reference Citation Analysis]
2 Cusack R, Garduno A, Elkholy K, Martín-Loeches I. Novel investigational treatments for ventilator-associated pneumonia and critically ill patients in the intensive care unit. Expert Opin Investig Drugs 2022. [PMID: 35040388 DOI: 10.1080/13543784.2022.2030312] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Isler B, Harris P, Stewart AG, Paterson DL. An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa--authors' response. J Antimicrob Chemother 2021;76:3327-8. [PMID: 34624086 DOI: 10.1093/jac/dkab366] [Reference Citation Analysis]
4 Lee YL, Ko WC, Lee WS, Lu PL, Chen YH, Cheng SH, Lu MC, Lin CY, Wu TS, Yen MY, Wang LS, Liu CP, Shao PL, Shi ZY, Chen YS, Wang FD, Tseng SH, Lin CN, Chen YH, Sheng WH, Lee CM, Tang HJ, Hsueh PR. In-vitro activity of cefiderocol, cefepime/zidebactam, cefepime/enmetazobactam, omadacycline, eravacycline and other comparative agents against carbapenem-nonsusceptible Enterobacterales: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2017-2020. Int J Antimicrob Agents 2021;58:106377. [PMID: 34166777 DOI: 10.1016/j.ijantimicag.2021.106377] [Reference Citation Analysis]
5 Vázquez-Ucha JC, Lasarte-Monterrubio C, Guijarro-Sánchez P, Oviaño M, Álvarez-Fraga L, Alonso-García I, Arca-Suárez J, Bou G, Beceiro A. Reply to Shapiro, "Cefepime/Enmetazobactam Is a Clinically Effective Combination Targeting Extended-Spectrum β-Lactamase-Producing Enterobacterales". Antimicrob Agents Chemother 2022;:e0035322. [PMID: 35471039 DOI: 10.1128/aac.00353-22] [Reference Citation Analysis]
6 Jean SS, Ko WC, Lee WS, Lu MC, Hsueh PR; SMART Program. Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020. Expert Rev Anti Infect Ther 2021. [PMID: 34933656 DOI: 10.1080/14787210.2022.2021876] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
7 Principe L, Lupia T, Andriani L, Campanile F, Carcione D, Corcione S, Rosa FGD, Luzzati R, Stroffolini G, Steyde M, Decorti G, Bella SD. Microbiological, Clinical, and PK/PD Features of the New Anti-Gram-Negative Antibiotics: β-Lactam/β-Lactamase Inhibitors in Combination and Cefiderocol—An All-Inclusive Guide for Clinicians. Pharmaceuticals 2022;15:463. [DOI: 10.3390/ph15040463] [Reference Citation Analysis]
8 Pan X, Zhao X, Song Y, Ren H, Tian Z, Liang Q, Jin Y, Bai F, Cheng Z, Feng J, Wu W. Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate. Microbiol Spectr 2022;10:e0267821. [PMID: 35196805 DOI: 10.1128/spectrum.02678-21] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Karaiskos I, Galani I, Papoutsaki V, Galani L, Giamarellou H. Carbapenemase producing Klebsiella pneumoniae: implication on future therapeutic strategies. Expert Rev Anti Infect Ther 2021;:1-17. [PMID: 34033499 DOI: 10.1080/14787210.2021.1935237] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Nicolau DP, Bhagwat SS, Abdelraouf K. Comment on: An update on cefepime and its future role in combination with novel β-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa. J Antimicrob Chemother 2021:dkab229. [PMID: 34179957 DOI: 10.1093/jac/dkab229] [Cited by in F6Publishing: 1] [Reference Citation Analysis]